Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Comment by commissionson May 06, 2004 9:39am
120 Views
Post# 7449398

RE: further thoughts

RE: further thoughtsSS, yes a reverse split is going to happen but not the way you are looking at it. Peters calls it the Canadian 2-step, Amex first, to get a reasonable runup- $3-$5 US, then a rollback of 2:1 for the Nasdaq. This extra financing obviously is going to be well used in the long but its primary purpose today is to get the share number up such that the market cap is well above $100 million to facilitate the move to the Amex. Their Merchant Banker ' Handlers' in the US know exactly what they are doing.No one makes money if the stock is rolled back now to go to the Nasdaq first. Do you not think its in everyone's best interests to get Nasdaq listed? Let the money people do what they are good at. Just a hint, why don't you due some intricate Due Diligence and find out who some of UBS'big CLIENTS are, and perhaps you might be a little more at ease. 200 million shares after this financing(fully diluted) may seem like alot, but not when every institution in the US wants to get a piece of this pie.I don't think you know this but they approx 200 analysts confirmed to be talking to them at ASCO. End result if only you get coverage from 30-40 houses and on top of that probably the same-30-40 market makers handling them on the Amex what do you think is going to happen.Let me put that in perspective currently they have only 1 analyst covering them- Parcash Dowd at Canaccord ,and one smalltime Mickey Mouse market maker who has been invisible- Latimer. No disrespect SS but maybe you have never been in a situation where you are going to make some serious money and are a little jittery. Serious meaning $500k and up. These people are going to allow alot people the option of retiring and I hope that you are in that number and we can sit back after its all over and have a beer and laugh about it. Commissions PS just sit back and enjoy the ride.
Bullboard Posts